Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Corix Bioscience's 3-Year ROIIC % for the quarter that ended in Dec. 2016 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Corix Bioscience's 3-Year ROIIC % or its related term are showing as below:
CXBS's 3-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.635 * Ranked among companies with meaningful 3-Year ROIIC % only.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Corix Bioscience 3-Year ROIIC % Related Terms
Corix Bioscience 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Corix Bioscience's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CXBS vs BKIT, YBAO, HSTI: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corix Bioscience 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Corix Bioscience's 3-Year ROIIC % falls into.
Corix Bioscience's 3-Year ROIIC % for the quarter that ended in Dec. 2016 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.854 (Dec. 2016) - -1.702 (Jan. 2013) )
/
( 11.452 (Dec. 2016) - 0.008 (Jan. 2013) )
=
-2.152
/
11.444
=
-18.80%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Corix Bioscience (CXBS) has a 3-Year ROIIC % of 0.00 as of Dec. 2016. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's 3-Year ROIIC % too high?
Corix Bioscience's current 3-Year ROIIC % is 0.00.
How does Corix Bioscience's 3-Year ROIIC % compare to BKIT and YBAO?
Corix Bioscience's 3-Year ROIIC % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year ROIIC % is 3.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Corix Bioscience and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corix Bioscience's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current 3-Year ROIIC % is 0.00 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXBS has been successfully added to your 
